KR101746872B1 - 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법 - Google Patents

단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법 Download PDF

Info

Publication number
KR101746872B1
KR101746872B1 KR1020117030122A KR20117030122A KR101746872B1 KR 101746872 B1 KR101746872 B1 KR 101746872B1 KR 1020117030122 A KR1020117030122 A KR 1020117030122A KR 20117030122 A KR20117030122 A KR 20117030122A KR 101746872 B1 KR101746872 B1 KR 101746872B1
Authority
KR
South Korea
Prior art keywords
ala
pro
arg
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117030122A
Other languages
English (en)
Korean (ko)
Other versions
KR20120087805A (ko
Inventor
데보라 롱
제시카 플레흐트너
모지카 스코베른
조지 알. 시베르
Original Assignee
제노시아 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제노시아 바이오사이언스, 인크. filed Critical 제노시아 바이오사이언스, 인크.
Publication of KR20120087805A publication Critical patent/KR20120087805A/ko
Application granted granted Critical
Publication of KR101746872B1 publication Critical patent/KR101746872B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020117030122A 2009-05-22 2010-05-24 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법 Expired - Fee Related KR101746872B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US61/180,784 2009-05-22
US23562809P 2009-08-20 2009-08-20
US61/235,628 2009-08-20
US24058709P 2009-09-08 2009-09-08
US24062609P 2009-09-08 2009-09-08
US61/240,626 2009-09-08
US61/240,587 2009-09-08
US30591810P 2010-02-18 2010-02-18
US61/305,918 2010-02-18
PCT/US2010/035998 WO2010135747A1 (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (2)

Publication Number Publication Date
KR20120087805A KR20120087805A (ko) 2012-08-07
KR101746872B1 true KR101746872B1 (ko) 2017-06-14

Family

ID=43126545

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117030122A Expired - Fee Related KR101746872B1 (ko) 2009-05-22 2010-05-24 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법

Country Status (17)

Country Link
US (3) US8617564B2 (enExample)
EP (3) EP2432504B1 (enExample)
JP (2) JP5771605B2 (enExample)
KR (1) KR101746872B1 (enExample)
CN (2) CN102458463B (enExample)
AU (1) AU2010249330B2 (enExample)
BR (1) BRPI1012811A2 (enExample)
CA (1) CA2797937C (enExample)
ES (1) ES2732815T3 (enExample)
IL (1) IL216508A (enExample)
MX (1) MX2011012347A (enExample)
MY (1) MY159500A (enExample)
NZ (1) NZ597182A (enExample)
RU (1) RU2585961C9 (enExample)
SG (1) SG176207A1 (enExample)
WO (2) WO2010135747A1 (enExample)
ZA (1) ZA201109444B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
EP2643014A4 (en) * 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
JP6199878B2 (ja) * 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
EA034351B1 (ru) * 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
US20140093537A1 (en) * 2012-09-30 2014-04-03 Nanobio Corporation Immunogenic compositions comprising nanoemulsion and methods of administering the same
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
WO2015134368A2 (en) 2014-03-03 2015-09-11 Albert Einstein College Of Medicine Of Yeshiva University Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
RS62747B1 (sr) 2016-02-01 2022-01-31 Simplexia Ab Skraćeni glikoprotein g herpes simpleks virusa 2
HUE049237T2 (hu) * 2016-04-08 2020-09-28 Krystal Biotech Inc Készítmények a bõr sérülései, rendellenességei és betegségei kezelési eljárásaiban történõ alkalmazásra
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
EP3615060A4 (en) 2017-04-26 2021-06-09 Merck Sharp & Dohme Corp. HSV ANTIGEN PEPTIDS AND HSV PROTEIN VACCINES
EP4242223A3 (en) * 2017-08-17 2024-03-13 The Trustees of The University of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
CN113747925B (zh) 2019-03-21 2024-10-15 隆萨销售股份公司 胞外囊泡缀合物及其用途
PH12021552223A1 (en) 2019-03-21 2022-05-30 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CN117412986A (zh) 2021-04-02 2024-01-16 克里斯托生物技术股份有限公司 用于癌症疗法的病毒载体
IL311239A (en) 2021-09-09 2024-05-01 Affinivax Inc Multivalent pneumococcal vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016779A1 (en) * 1993-12-14 1995-06-22 Smithkline Beecham Biologicals (S.A.) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) * 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) * 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
ATE179614T1 (de) * 1990-08-02 1999-05-15 Chiron Corp Herpes simplex virus vp16 impfstoffe
DK31991D0 (da) * 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994029456A2 (en) 1993-06-08 1994-12-22 Abbott Laboratories Herpes simplex virus type-2 protease
CN1133594A (zh) 1993-08-20 1996-10-16 史密丝克莱恩比彻姆公司 单纯性疱疹病毒-2ul26基因，衣壳蛋白，免疫测定和蛋白酶抑制剂
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) * 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
KR100564268B1 (ko) * 1996-10-23 2006-03-27 와이어쓰 백신
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
CA2270282A1 (en) 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
WO1998055145A1 (en) 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) * 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
TR200002608T2 (tr) * 1998-03-09 2000-11-21 Smithkline Beecham Biologicals S.A Kombine aşı kompozisyonları
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CN1348463A (zh) * 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
EP1185662B1 (fr) * 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CN1376201A (zh) * 1999-09-30 2002-10-23 华盛顿大学 免疫学上重要的单纯疱疹病毒抗原
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
ES2258987T3 (es) 1999-12-17 2006-09-16 Wyeth Holdings Corporation Vacuna para reforzar las respuestas inmunitarias al virus del herpes simple.
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
AU2001273128C1 (en) 2000-06-29 2006-09-21 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
DE60131975T2 (de) * 2000-07-27 2008-12-18 The Trustees Of The University Of Pennsylvania Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20020094337A1 (en) * 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
US7314624B2 (en) 2001-06-05 2008-01-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
ATE488249T1 (de) * 2001-07-31 2010-12-15 Univ Washington Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
WO2003020108A2 (en) 2001-09-04 2003-03-13 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
ATE414176T1 (de) * 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
US7267940B2 (en) * 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
JP5492418B2 (ja) * 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
EP2001516A4 (en) 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
EP2521786B1 (en) * 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
AU2007292905B2 (en) * 2006-09-08 2013-05-23 The Trustees Of The University Of Pennsyvania HSV-1 and HSV-2 vaccines and methods of use thereof
WO2008140478A2 (en) 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009006618A2 (en) 2007-07-05 2009-01-08 University Of Kansas Herpes simplex virus mutant icp0 protein
AU2008274887B2 (en) 2007-07-06 2013-10-31 The University Of Sydney Epitopes of herpes simplex virus
US20090291095A1 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion adjuvants
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
EP3413049B1 (en) 2008-07-01 2020-10-28 Genocea Biosciences Inc. Antigen screening system
CA2781805A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
WO2010103017A2 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
DK2544693T3 (en) 2010-03-09 2017-12-04 Biomedical Res Models Inc Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2
WO2012054755A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016779A1 (en) * 1993-12-14 1995-06-22 Smithkline Beecham Biologicals (S.A.) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition

Also Published As

Publication number Publication date
EP2432504A4 (en) 2013-07-31
EP3756684A1 (en) 2020-12-30
JP5771605B2 (ja) 2015-09-02
EP2432504A1 (en) 2012-03-28
JP2015178529A (ja) 2015-10-08
ZA201109444B (en) 2016-09-28
US9895436B2 (en) 2018-02-20
MX2011012347A (es) 2012-02-21
US8617564B2 (en) 2013-12-31
CN106924728A (zh) 2017-07-07
CN102458463A (zh) 2012-05-16
EP2432504B1 (en) 2019-05-01
SG176207A1 (en) 2011-12-29
WO2010135749A1 (en) 2010-11-25
KR20120087805A (ko) 2012-08-07
WO2010135749A9 (en) 2011-07-21
JP2012527486A (ja) 2012-11-08
US20100330112A1 (en) 2010-12-30
AU2010249330A1 (en) 2012-01-19
US20140227307A1 (en) 2014-08-14
US10653771B2 (en) 2020-05-19
BRPI1012811A2 (pt) 2016-03-29
ES2732815T3 (es) 2019-11-26
IL216508A0 (en) 2012-02-29
CA2797937C (en) 2020-01-14
CN102458463B (zh) 2017-01-18
RU2011147153A (ru) 2013-06-27
MY159500A (en) 2017-01-13
US20180369365A1 (en) 2018-12-27
CN106924728B (zh) 2021-02-05
JP6096839B2 (ja) 2017-03-15
NZ597182A (en) 2014-07-25
WO2010135747A1 (en) 2010-11-25
EP3590533A1 (en) 2020-01-08
IL216508A (en) 2016-08-31
CA2797937A1 (en) 2010-11-25
RU2585961C2 (ru) 2016-06-10
RU2585961C9 (ru) 2016-12-27
AU2010249330B2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
KR101746872B1 (ko) 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법
US10350288B2 (en) Methods and compositions for treating herpes
AU2011336894B2 (en) Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP2782597B1 (en) Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230608

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230608